DDN Content Team
The DDN Content Team brings leverages AI-assisted tools that help research, draft, and refine content. This partnership allows the team to keep pace with fast-moving science news while maintaining the accuracy and clarity scientists and industry professionals rely on.
Articles by DDN Content Team
| 5 min read
Oncology proved the case. Now spatial biology is spreading across therapeutic areas and modalities. This hub looks at where it goes next.
| 7 min read
Scaling up used to mean starting over. With consistent geometry and mixing design, bench-to-commercial bioreactor translation is becoming predictable.
| 8 min read
Stainless steel is strong, but flexibility is faster. Single-use technology is rewriting the economics of biopharmaceutical facility design.
| 10+ min read
The hardest part of drug discovery isn't finding the molecule. It's making a million doses of it reliably, safely, and at commercial scale.
| 3 min read
From vein-to-vein tracking to the plasmid bottleneck, logistics are the new efficacy endpoint
| 3 min read
The "make or buy" decision is no longer just about cost, but about the survival of the therapy itself.
| 3 min read
Simulating the future is helping the industry abandon the "black box" of bioreactor biology.
| 3 min read
The industry is pivoting from "grams to tons" to meet the demand for population-level RNA therapeutics.
| 3 min read
Targeted protein degradation is rewriting the rules of pharmacology and drugging the "undruggable."
| 4 min read
Why the "maximum tolerated dose" is obsolete for drugs that act like code.
| 4 min read
From high-dose toxicity to commercial withdrawal, the path to a cure is paved with cautionary tales.
| 3 min read
As the modality matures, safety signals and manufacturing hurdles force a regulatory rethink.
